MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
CIPL

CIPLA.BO

Cipla Limited

$1371.45
-0.8
 (-0.06%)
Exchange:  BSE
Market Cap:  1.116T
Shares Outstanding:  806.358M
Delayed data
Calculate CIPLA.BO Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Drug Manufacturers – Specialty & GenericView industry performance
   
CEO:  Achin Gupta
Full Time Employees:  31369
Address: 
Cipla House
Mumbai
MA
400013
IN
Website:  https://www.cipla.com
Operating globally across India, the United States, South Africa, and other international markets, Cipla Limited, along with its affiliated entities, is engaged in the production, advancement, and distribution of pharmaceutical goods. Its operations are structured into two principal divisions: Pharmaceuticals and New Ventures. Beyond active pharmaceutical ingredients (APIs), the company delivers diverse formulations addressing a wide array of therapeutic areas. These encompass cardio-metabolic conditions (including treatments for MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities, diabetes, and obesity), HIV, respiratory disorders, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women’s health, ophthalmology, and neuropsychiatry. Its specialized respiratory portfolio features inhalers and nasal sprays, complemented by other related offerings such as injectables and biosimilar treatments. A specific product noteworthy is Easylax and Easylax L, a liquid paraffin solution designed to alleviate constipation. Established in 1935, Cipla Limited maintains its corporate headquarters in Mumbai, India.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
CICIPLA.BO logoCIPLA.BOCipla Limited1.12T33.42,5280.0%
TATAK logoTAKTakeda Pharmaceutical Company Limited60.2B52.341.32.4%
TETEVA logoTEVATeva Pharmaceutical Industries Limited45.4B62.519.79.0%
HLHLN logoHLNHaleon plc40.9B18.816.16.5%
ZTZTS logoZTSZoetis Inc.30.0B11.811.421.6%
VTVTRS logoVTRSViatris Inc.19.7B—6.9-0.2%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202420252026
Revenue255,367,100272,674,400281,625,900
Gross Profit164,927,600180,921,400120,361,700
EBITDA61,906,70070,221,40064,809,500
Operating Income94,795,800105,005,80047,139,400
Net Income41,215,50052,725,20038,792,300

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202420252026
Total Assets327,178,200373,870,400424,959,800
Total Liabilities59,152,90060,977,90079,757,400
Total Stockholders Equity267,066,300311,934,500344,319,500
Total Debt5,603,0004,394,3006,137,700
Cash and Cash Equivalents6,400,7005,886,90013,074,200

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202420252026
Operating Cash Flow41,339,10050,049,80041,259,100
Capital Expenditure-13,493,000-11,621,600-15,993,300
Free Cash Flow27,846,10038,428,20025,265,800
Net Income41,215,50052,725,20038,792,300
Net Change in Cash-489,900303,1006,890,100

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)407,775,075.429Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)455,284,648.168Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)431,700,000Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)126,476,863.007Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)143,490,151.277Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)135,044,434.430Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)80,769,302.705Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)93,221,971.737Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)87,040,232.207Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)92,666,104.911Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)103,462,564.325Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)98,102,998.198Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)107.700Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)115.350Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)99.940Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)8Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)7Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
4
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
33.41
?Enterprise Value
 (TTM)
: 
1.127T  ?EV/FCF
 (TTM)
: 
165.59
?Dividend Yield
 (TTM)
: 
0.93%  ?Payout Ratio
 (TTM)
: 
38.34%
?ROE
 (TTM)
: 
10%  ?ROIC
 (TTM)
: 
0%
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
0
?P/B
 (TTM)
: 
3.26  ?Current Ratio
 (TTM)
: 
0

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
2,528.43Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about CIPLA.BO valuation

Is Cipla Limited (CIPLA.BO) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Cipla Limited (CIPLA.BO) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is CIPLA.BO a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether CIPLA.BO trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is CIPLA.BO’s P/E ratio?

You can see CIPLA.BO’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for CIPLA.BO?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is CIPLA.BO a good long-term investment?

Whether CIPLA.BO fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

CIPLA.BO

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-0.06
MARKETSnap

Trading Metrics:

Open: 1372.25   Previous Close: 1372.25
Day Low: 1371.45   Day High: 1391.7
Year Low: 1283   Year High: 1672.2
Price Avg 50: 1456.22   Price Avg 200: 1507.22
Volume: 11566   Average Volume: 103143

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • Learn
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read